Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022
12 sept. 2022 07h00 HE
|
Plus Therapeutics Inc.
Phase 1 data indicates that direct administration of 186RNL targeted radiotherapeutic is safe in patients with recurrent glioblastoma Statistically significant overall survival benefit observed with...
Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
08 sept. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate
06 sept. 2022 07h00 HE
|
Plus Therapeutics Inc.
NIH-funded ReSPECT-GBM Phase 2 trial to start in 2022 ReSPECT-GBM Phase 2 to focus on 186RNL dose expansion, safety and efficacy data to support future registrational trial AUSTIN, Texas, Sept. 06,...
Plus Therapeutics Announces Summary of FDA Meeting on Company’s cGMP Manufacturing Process for Lead Drug Candidate
29 août 2022 07h00 HE
|
Plus Therapeutics Inc.
cGMP production of 186RNL targeted radiotherapeutic beginning in second half of 2022 to support ongoing and future ReSPECT™ clinical trials AUSTIN, Texas, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Plus...
Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022
23 août 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Awarded $17.6 Million from State of Texas
17 août 2022 17h46 HE
|
Plus Therapeutics Inc.
Funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the second largest global public funder of cancer research, will support the majority of the development costs of 186RNL for...
Plus Therapeutics Announces Share Repurchase Program
15 août 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
13 août 2022 13h06 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
28 juil. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit
27 juil. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...